financetom
Business
financetom
/
Business
/
B2Gold Q3 adjusted net income misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
B2Gold Q3 adjusted net income misses estimates
Nov 5, 2025 3:33 PM

Overview

* B2Gold Q3 2025 revenue and adjusted net income missed analyst expectations

* Gold production of 254,369 ounces in Q3 2025

* Company achieved commercial production at Goose Mine on October 2, 2025

Outlook

* B2Gold ( BTG ) maintains 2025 production guidance for Fekola, Masbate, and Otjikoto mines

* Company lowers Goose Mine 2025 production guidance to 50,000-80,000 ounces

* B2Gold ( BTG ) updates Fekola Complex all-in sustaining cost guidance to $1,670-$1,730 per ounce

Result Drivers

* HIGHER PRODUCTION - Fekola, Masbate, and Otjikoto mines exceeded expected production, contributing to higher overall gold output

* COST REDUCTION - Lower fuel costs and favorable foreign exchange rates reduced cash operating costs

* GUIDANCE REVISION - Goose Mine production guidance lowered due to crushing plant issues and ore access delays

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $782.95 $876.80

Revenue mln mln (2

Analysts

)

Q3 EPS $0.01

Q3 Miss $179.91 $223.80

Adjusted mln mln (2

Net Analysts

Income )

Q3 Net $23.12

Income mln

Q3 Basic $0.01

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the gold peer group is "buy"

* Wall Street's median 12-month price target for B2Gold Corp ( BTG ) is C$8.00, about 28.7% above its November 5 closing price of C$5.70

* The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
Sep 23, 2025
03:43 AM EDT, 09/23/2025 (MT Newswires) -- Tianyi Jiang, Director, Chief Executive Officer, on September 18, 2025, sold 2,068,966 shares in AvePoint ( AVPT ) for $31,468,973. Following the Form 4 filing with the SEC, Jiang has control over a total of 13,841,853 common shares of the company, with 13,841,853 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029638/xslF345X05/rdgdoc.xml ...
Rocket Lab Insider Sold Shares Worth $41,985,316, According to a Recent SEC Filing
Rocket Lab Insider Sold Shares Worth $41,985,316, According to a Recent SEC Filing
Sep 23, 2025
03:38 AM EDT, 09/23/2025 (MT Newswires) -- Adam C. Spice, Chief Financial Officer, on September 18, 2025, sold 874,588 shares in Rocket Lab ( RKLB ) for $41,985,316. Following the Form 4 filing with the SEC, Spice has control over a total of 2,057,889 common shares of the company, with 2,057,889 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1819994/000200101125000080/xslF345X05/edgardoc.xml ...
EXPLAINER-Why is leucovorin being considered as an autism treatment?
EXPLAINER-Why is leucovorin being considered as an autism treatment?
Sep 23, 2025
(Adds detail about GSK in paragraph 3) By Nancy Lapid Sept 23 (Reuters) - On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by GlaxoSmithKline that the company had previously withdrawn from the FDA's consideration when it stopped manufacturing the...
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
Sep 23, 2025
03:42 AM EDT, 09/23/2025 (MT Newswires) -- James Caci, Chief Financial Officer, on September 18, 2025, sold 216,000 shares in AvePoint ( AVPT ) for $3,285,360. Following the Form 4 filing with the SEC, Caci has control over a total of 213,030 common shares of the company, with 213,030 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029637/xslF345X05/rdgdoc.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved